Result of WRAP Retail Offer

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms, further to the announcements made on 22 July 2025, the result of its WRAP Retail Offer at the Issue Price of 0.5 pence per share. The Company announces that it has raised aggregate gross proceeds of approximately £0.43 million pursuant to the WRAP Retail Offer in addition to the previously announced Placing and Subscription. Accordingly, the Company will issue a total of 86,286,792 new Ordinary Shares at the Issue Price pursuant to the WRAP Retail Offer (the "WRAP Retail Offer Shares").

In total, the Fundraising has raised gross proceeds of approximately £6.35 million for the Company, via the Placing and Subscription of 1,183,087,396 Placing and Subscription Shares and the 86,286,792 WRAP Retail Offer Shares.

The total proceeds from the Fundraising of £6.35 million, will extend the Company's cash runway into H2 2026.

Additionally, the Company has agreed to issue 1,478,472 new Ordinary Shares at the Issue Price of 0.5 pence per share to an adviser of the Company in lieu of fees in respect of the Fundraise.

Admission and Total Voting Rights

Applications have been made for the new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to become effective on or around 30 July 2025.

Upon Admission, the Company's issued ordinary share capital will consist of 1,513,394,127 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 1,513,394,127. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The new Ordinary Shares to be issued will be issued free of all liens, charges and encumbrances and will, on Admission, rank pari passu in all respects with the new Ordinary Shares to be issued pursuant to the Placing, the Subscription and the Company's existing Ordinary Shares.

Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7am on 21 July 2025